Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Latest-iteration self-expanding vs balloon-expandable transcatheter heart valves for failed surgical bioprostheses: The INNOVATE registry.

Created on 19 Nov 2026

Authors

Antonio Sisinni, Antonio Popolo Rubbio, Azeem Latib, Ignacio J Amat Santos, Christina Brinkmann, Cristina Aurigemma, Claudio Montalto, Damiano Regazzoli, Carmine Musto, Giuseppe Massimo Sangiorgi, Zhou Yijiang, Rodrigo Estévez-Loureiro, Victor Alfonso Jimenez Diaz, Gaspare Sergio Cannone, Pier Pasquale Leone, Raffaele Del Maso, Alexandra M Rojas Sanchez, Nedy Brambilla, Francesco Burzotta, Jacopo A Oreglia, Joachim Schofer, Francesco Bedogni, Luca Testa

Published in

European heart journal. Valvular and structural heart disease. Volume 2. Issue 3. Pages xwag042. Epub Jun 01, 2026.

Abstract

Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is increasingly performed in degenerated surgical bioprostheses, although data concerning the performance of latest iterations of transcatheter heart valves (THVs) are scarce.
We aimed to compare procedural, clinical and haemodynamic outcomes of latest-generation THVs in ViV TAVI.
This multicenter retrospective study included 381 consecutive patients undergoing ViV TAVI, 294 with self-expanding (SE), and 87 with a balloon expandable (BE) THV. Primary efficacy endpoints were Valve Academic Research Consortium (VARC)-3 technical and device success. Primary safety outcomes were all-cause death and re-hospitalization for heart failure (HF). Patients receiving SE valves were older (79 vs 75 years, P < .001). Time from surgery to ViV was longer in BE group (4 vs 3 years, P = .041). A numerically higher rate of coronary obstruction (4% vs 0%, P = .076) was observed in SE THVs, despite a more frequent coronary protection (24% vs 14%, P = .045). Technical (95% vs 98%, P = .380) and device success (89% vs 79%, P = .105) were similar. At 1 year, SE valves showed significantly lower mean gradients (14 ± 8 vs 21 ± 8 mmHg, P < .001). Rates of paravalvular leak and patient-prosthesis mismatch did not differ between groups. All-cause mortality (5% vs 4%, P = .928) and re-hospitalization for HF (4% vs 2%, P = .507) was also comparable among SE and BE, likewise myocardial infarction, stroke, and permanent pacemaker implantation.
Latest iterations of SE and BE THVs provided favourable outcomes in ViV TAVI, without significant differences in safety/efficacy profile. SE platforms achieved lower residual gradients at 1 year.

PMID:
43053885
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement